Hypertonic nasogastric tube feedings: do they cause diarrhea?
Hypertonic NG tube feeding in hospitalized patients, whether on the hospital ward or in the ICU, is considered a common etiology of diarrhea. To evaluate the accuracy of this assumption, five normal volunteers, ten hospitalized postoperative patients with head and neck cancer, and 24 ICU patients were given hypertonic (690 mosm), low residue, lactose-free tube feedings starting at 30 kcal/kg.day. There was no prior history of diarrhea in any of the groups studied. There was a significant difference in albumin levels between the three groups, with an average albumin of 2.8 g/dl in the ICU patient group; different from 4.5 g/dl present in both the normal volunteer and non-ICU hospitalized patient groups (general linear models procedure from SAS, p less than .05) (Duncan test). Diarrhea was not present in the normal volunteers or non-ICU patients during the feedings, but did occur in 3/24 ICU patients. This difference was not significant. The three patients with diarrhea had an average albumin level of 3.0 g/dl, while the other ICU patients had an average albumin of 2.7 g/dl. We conclude that hypertonic NG tube feedings do not cause diarrhea in normal volunteers or postoperative head and neck cancer patients. However, in a small statistically insignificant percent of mechanically ventilated ICU patients, this regimen may cause diarrhea although no risk factors can be identified.
Pesola
G R
GR
Department of Anesthesiology and Critical Care Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Hogg
J E
JE
Eissa
N
N
Matthews
D E
DE
Carlon
G C
GC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000032:analysis; D015984:Causality; D003422:Critical Care; D003672:Defecation; D003967:Diarrhea / Q000453:epidemiology / Q000209:etiology*; D004750:Enteral Nutrition / Q000009:adverse effects* / Q000592:standards; D005069:Evaluation Studies as Topic; D005260:Female; D005526:Food, Formulated / Q000009:adverse effects* / Q000032:analysis; D006258:Head and Neck Neoplasms / Q000601:surgery / Q000628:therapy; D006801:Humans; D006982:Hypertonic Solutions / Q000009:adverse effects*; D007441:Intubation, Gastrointestinal / Q000295:instrumentation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012121:Respiration, Artificial
D000418:Albumins; D006982:Hypertonic Solutions